Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer

Sara A. Hurvitz, MD
Published: Thursday, Mar 14, 2019



Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive metastatic breast cancer.

The number of therapies currently in development is phenomenal, Hurvitz says, but it is going to take a highly active agent to challenge the established gold standards in the frontline and second-line settings. In the frontline setting, the combination of trastuzumab (Herceptin), pertuzumab (Perjeta), and a taxane has yielded a median overall survival of about 56 months. That is a survival benefit of almost 5 years, Hurvitz notes, quite a threshold for a new therapy to beat.

Similarly, in the second-line setting, the use of ado-trastuzumab emtansine (T-DM1; Kadcyla) has led to encouraging responses when compared with lapatinib and capecitabine, a combination that has garnered attention in recent studies. With that being said, drugs like trastuzumab deruxtecan (DS-8201) seem up to the challenge based on early data. There could be a new standard of care in the next 4 to 5 years, Hurvitz concludes.
SELECTED
LANGUAGE


Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive metastatic breast cancer.

The number of therapies currently in development is phenomenal, Hurvitz says, but it is going to take a highly active agent to challenge the established gold standards in the frontline and second-line settings. In the frontline setting, the combination of trastuzumab (Herceptin), pertuzumab (Perjeta), and a taxane has yielded a median overall survival of about 56 months. That is a survival benefit of almost 5 years, Hurvitz notes, quite a threshold for a new therapy to beat.

Similarly, in the second-line setting, the use of ado-trastuzumab emtansine (T-DM1; Kadcyla) has led to encouraging responses when compared with lapatinib and capecitabine, a combination that has garnered attention in recent studies. With that being said, drugs like trastuzumab deruxtecan (DS-8201) seem up to the challenge based on early data. There could be a new standard of care in the next 4 to 5 years, Hurvitz concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x